Interim guidance for country validation of viral hepatitis elimination. https://www.whoint/publications/i/item/9789240028395. Accessed 08 Oct 2024.

Polaris Observatory HCV Collaborators. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study. Lancet Gastroenterol Hepatol. 2022;7(5):396–415.

Article  Google Scholar 

Huang CF, Tseng KC, Cheng PN, Hung CH, Lo CC, Peng CY, et al. Impact of sofosbuvir-based direct-acting antivirals on renal function in chronic hepatitis C patients with impaired renal function: a large cohort study from the nationwide HCV registry program (TACR). Clin Gastroenterol Hepatol. 2022;20(5):1151-1162.e1156.

Article  PubMed  CAS  Google Scholar 

Huang CF, Lai HC, Chen CY, Tseng KC, Kuo HT, Hung CH, et al. Extrahepatic malignancy among patients with chronic hepatitis C after antiviral therapy: a real-world nationwide study on Taiwanese Chronic Hepatitis C Cohort (T-COACH). Am J Gastroenterol. 2020;115(8):1226–35.

Article  PubMed  Google Scholar 

Huang CF, Yeh ML, Huang CI, Liang PC, Lin YH, Lin ZY, et al. Post-treatment fibrotic modifications overwhelm pretreatment liver fibrosis in predicting HCC in CHC patients with curative antivirals. Hep Intl. 2018;12(6):544–51.

Article  Google Scholar 

Tanaka Y, Ogawa E, Huang CF, Toyoda H, Jun DW, Tseng CH, et al. HCC risk post-SVR with DAAs in East Asians: findings from the REAL-C cohort. Hep Intl. 2020;14(6):1023–33.

Article  Google Scholar 

Yu ML, Huang CF, Yeh ML, Tsai PC, Huang CI, Hsieh MH, et al. Time-degenerative factors and the risk of hepatocellular carcinoma after antiviral therapy among hepatitis C virus patients: a model for prioritization of treatment. Clin Cancer Res. 2017;23(7):1690–7.

Article  PubMed  CAS  Google Scholar 

Hsu WF, Tsai PC, Chen CY, Tseng KC, Lai HC, Kuo HT, et al. Hepatitis C virus eradication decreases the risks of liver cirrhosis and cirrhosis-related complications (Taiwanese chronic hepatitis C cohort). J Gastroenterol Hepatol. 2021;36(10):2884–92.

Article  PubMed  Google Scholar 

Marcellin F, Roux P, Protopopescu C, Duracinsky M, Spire B, Carrieri MP. Patient-reported outcomes with direct-acting antivirals for the treatment of chronic hepatitis C: current knowledge and outstanding issues. Expert Rev Gastroenterol Hepatol. 2017;11(3):259–68.

PubMed  CAS  Google Scholar 

Huang CF, Awad MH, Gal-Tanamy M, Yu ML. Unmet needs in the post-direct-acting antivirals era: the risk and molecular mechanisms of hepatocellular carcinoma after hepatitis C virus eradication. Clin Mol Hepatol. 2024;30(3):326–44.

Article  PubMed  PubMed Central  Google Scholar 

Waziry R, Hajarizadeh B, Grebely J, Amin J, Law M, Danta M, et al. Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: a systematic review, meta-analyses, and meta-regression. J Hepatol. 2017;67(6):1204–12.

Article  PubMed  CAS  Google Scholar 

Chuang WL, Chien RN, Peng CY, Chang TT, Lo GH, Sheen IS, et al. Ledipasvir/sofosbuvir fixed-dose combination tablet in Taiwanese patients with chronic genotype 1 hepatitis C virus. J Gastroenterol Hepatol. 2016;31(7):1323–9.

Article  PubMed  CAS  Google Scholar 

Kao JH, Chien RN, Chang TT, Peng CY, Hu TH, Lo GH, et al. A phase 3b study of sofosbuvir plus ribavirin in Taiwanese patients with chronic genotype 2 hepatitis C virus infection. Liver Int. 2016;36(8):1101–7.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Ahn SH, Lim YS, Lee KS, Paik SW, Lee YJ, Jeong SH, et al. A phase 3b study of sofosbuvir plus ribavirin in treatment-naive and treatment-experienced Korean patients chronically infected with genotype 2 hepatitis C virus. J Viral Hepatitis. 2016;23(5):358–65.

Article  CAS  Google Scholar 

Lim YS, Ahn SH, Lee KS, Paik SW, Lee YJ, Jeong SH, et al. A phase IIIb study of ledipasvir/sofosbuvir fixed-dose combination tablet in treatment-naïve and treatment-experienced Korean patients chronically infected with genotype 1 hepatitis C virus. Hep Intl. 2016;10(6):947–55.

Article  Google Scholar 

Jang TY, Huang CF, Yeh ML, Huang CI, Dai CY, Tsai PC, et al. Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein expression predicts disease severity in nonalcoholic steatohepatitis patients. Kaohsiung J Med Sci. 2022;38(3):261–7.

Article  PubMed  CAS  Google Scholar 

Castera L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology. 2005;128(2):343–50.

Article  PubMed  Google Scholar 

Omata M, Cheng AL, Kokudo N, Kudo M, Lee JM, Jia J, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int. 2017;11(4):317–70.

Article  PubMed  Google Scholar 

He N, Feng G, Hao S, Xu M, Liu J, Kong F, et al. The impact of direct-acting antivirals on quality of life in patients with hepatitis C virus infection: a meta-analysis. Ann Hepatol. 2022;27(4): 100705.

Article  PubMed  CAS  Google Scholar 

Ioannou GN, Green PK, Berry K. HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma. J Hepatol. 2017;68:25–32.

Article  Google Scholar 

Kanda T, Goto T, Hirotsu Y, Moriyama M, Omata M. Molecular mechanisms driving progression of liver cirrhosis towards hepatocellular carcinoma in chronic hepatitis B and C infections: a review. Int J Mol Sci. 2019;20(6):1358.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Mukherjee S, Kar A, Khatun N, Datta P, Biswas A, Barik S. Familiarity breeds strategy: in silico untangling of the molecular complexity on course of autoimmune liver disease-to-hepatocellular carcinoma transition predicts novel transcriptional signatures. Cells. 2021;10(8):1917.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Berzigotti A, Tsochatzis E, Boursier J, Castera L, Cazzagon N, Friedrich-Rust M, Petta S, Thiele M. EASL clinical practice guidelines on non-invasive tests for evaluation of liver disease severity and prognosis—2021 update. J Hepatol. 2021;75(3):659–89.

Article  Google Scholar 

Koyama Y, Xu J, Liu X, Brenner DA. New developments on the treatment of liver fibrosis. Dig Dis. 2016;34(5):589–96.

Article  PubMed  Google Scholar 

Lin CL, Kao JH. Development of hepatocellular carcinoma in treated and untreated patients with chronic hepatitis B virus infection. Clin Mol Hepatol. 2023;29(3):605–22.

Article  PubMed  PubMed Central  Google Scholar 

Jun T, Hsu YC, Ogawa S, Huang YT, Yeh ML, Tseng CH, et al. Mac-2 binding protein glycosylation isomer as a hepatocellular carcinoma marker in patients with chronic hepatitis B or C infection. Hepatol Commun. 2019;3(4):493–503.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Sasaki R, Yamasaki K, Abiru S, Komori A, Nagaoka S, Saeki A, et al. Serum wisteria floribunda agglutinin-positive Mac-2 binding protein values predict the development of hepatocellular carcinoma among patients with chronic hepatitis C after sustained virological response. PLoS ONE. 2015;10(6): e0129053.

Article  PubMed  PubMed Central  Google Scholar 

Reiberger T, Lens S, Cabibbo G, Nahon P, Zignego AL, Deterding K, et al. EASL position paper on clinical follow-up after HCV cure. J Hepatol. 2024;81(2):326–44.

Article  PubMed  Google Scholar 

Huang CF, Awad MH, Gal-Tanamy M, Yu ML. Perspective of the risk and molecular mechanisms of hepatocellular carcinoma after HCV eradication in the post-DAA era. Clin Mol Hepatol. 2024;30(4):1023–5.

Article  PubMed  PubMed Central  Google Scholar 

Jang TY, Huang CF, Chang TS, Yang CC, Lo CC, Hung CH, et al. Impact of HCV eradication by directly acting antivirals on glycemic indices in chronic hepatitis C patients—a nationwide Taiwan HCV registry. J Formosan Med Assoc Taiwan yi zhi 2024:S0929-6646(24)00381-4.

Li J, Gordon SC, Rupp LB, Zhang T, Trudeau S, Holmberg SD, et al. Sustained virological response to hepatitis C treatment decreases the incidence of complications associated with type 2 diabetes. Aliment Pharmacol Ther. 2019;49(5):599–608.

Article  PubMed  PubMed Central  CAS  Google Scholar